• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    AstraZeneca Pharma India Ltd.
    01 May 2025
    9315.00
    4.11%
    AstraZeneca, Qure.ai complete AI-enabled assessment of 5 million chest X-rays for lung cancer
    Business Line
    In 2020, AstraZeneca partnered with Qure.ai to leverage its technology for assessing chest X-rays and determining potential lung cancer risk.
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd.'s price crossed above 30Day SMA today
    logo
    Alkem Laboratories Ltd.
    01 May 2025
    5096.40
    0.51%
    Alkem Lab's Sarvesh Singh buys duplex on Mumbai's Carter road for Rs 174 cr
    Business Standard
    The sea-facing duplex is spread across 12,148 square feet and occupies two entire floors.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.
    logo
    Gland Pharma Ltd.
    30 Apr 2025
    2058.30
    -2.08%
    Gland Pharma gets USFDA nod for Vyzulta generic with 180-day exclusivity
    Business Standard
    Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added. The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said. According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025. Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.
    Copy LinkShare onShare on Share on Share on
    Gland Pharma Ltd. has gained 15.54% in the last 1 Month
    logo
    Blue Jet Healthcare Ltd
    30 Apr 2025
    792.70
    -1.40%
    Broker's call: Blue Jet Healthcare (Buy)
    Business Line
    The company has established itself as a reliable supplier to its customers for the past three decades and is now working toward moving up the value chain by significantly increasing its investment in RD
    Copy LinkShare onShare on Share on Share on
    Blue Jet Healthcare Ltd has gained 78.32% in the last 1 Year
    Blue Jet Healthcare jumps 6% as MOFSL initiates coverage, 26% upside seen
    Business Standard | 30 Apr 2025, 02:55PM 1 more
    Blue Jet Healthcare Gets 'Buy' As Motilal Oswal Initiates Coverage, Sees 26% Upside
    NDTV Profit | 30 Apr 2025, 08:41AM
    logo
    AstraZeneca Pharma India Ltd.
    29 Apr 2025, 05:25PM
    9315.00
    4.11%
    AstraZeneca says potential US tariffs manageable; faces another China fine
    Business Standard
    "If tariffs were implemented in the range we have seen recently in other industries on medicines imported from Europe to the U.S., we would remain within the guidance range we indicated for 2025,"
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd.'s price crossed above 50Day SMA today
    logo
    Pfizer Ltd.
    29 Apr 2025, 04:54PM
    5258.00
    -0.36%
    Pfizer beats Q1 profit estimates on cost cut, strong sale of heart drug
    Business Standard
    It reported total revenue of $13.70 billion for the first quarter, compared with analysts' expectations of $13.91 billion, according to LSEG data
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading above its 200 day SMA of 4920.4
    logo
    Aurobindo Pharma Ltd.
    29 Apr 2025, 10:47AM
    1158.50
    0.03%
    Fire Incident halts production at Aurobindo Pharma subsidiary
    Business Line
    As a precautionary measure, operations at the plant will be suspended for an estimated 20 to 25 days while equipment is replaced
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Morepen Laboratories Ltd.
    29 Apr 2025, 10:16AM
    59.79
    -0.55%
    Morepen gets regulatory clearance for fatty liver drug development
    Business Line
    The shares of Morepen Laboratories Limited were trading at 62.36 up by 0.31 or 0.50 per cent on the NSE at 10 am
    Copy LinkShare onShare on Share on Share on
    Morepen Laboratories Ltd. is trading above its 100 day SMA of 58.4
    logo
    Natco Pharma Ltd.
    29 Apr 2025, 06:30AM
    972.00
    1.41%
    Stock to buy today: Natco Pharma (883.95)
    Business Line
    The upswing that followed has taken the stock above a notable resistance at 840 and both 20- and 50-day moving averages, turning the short-term outlook bullish
    Copy LinkShare onShare on Share on Share on
    Natco Pharma Ltd. has lost -27.83% in the last 1 Year
    logo
    Natco Pharma Ltd.
    29 Apr 2025, 06:30AM
    972.00
    1.41%
    Today's Stock Recommendation: April 29, 2025
    Business Line
    Will NATCO Pharma's stock trend this week?
    Copy LinkShare onShare on Share on Share on
    Natco Pharma Ltd. is trading above its 100 day SMA of 874.8
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd